Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

IBM offering free data services to support development of coronavirus-fighting drugs

By Sean Whooley | February 19, 2020

IBM (NYSE:IBM) announced today that it plans to work with medical institutions and practitioners by offering support in the development of drugs to combat the recent coronavirus outbreak.

The company said in a news release that it intends to leverage its IBM clinical development (ICD) system to help accelerate the development of key drugs in fighting the virus. ICD is a unified, SaaS-based data capture solution designed to offer end-to-end visibility and management capabilities for patients, sites and clinical trials.

ICD is also designed to reduce the time and cost of clinical trials through centralized and organized clinical trial details and a flexible and scalable data management platform.

IBM said its plan to assist in the coronavirus outbreak includes providing the ICD system for free to eligible applicable novel coronavirus-related clinical trials in China. The company also plans to offer commercially reasonable technology for free to support database construction and basic training for using ICD.

The company is among many medical device developers making an effort to help combat the coronavirus. IBM said hospitals, sponsors, CROs and R&D institutions that are researching novel coronavirus drugs and conducting related clinical trials are encouraged to contact the company.


Filed Under: Drug Discovery, Drug Discovery and Development
Tagged With: IBM
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50